Medical Oncology and Tumor Pharmacotherapy

, Volume 1, Issue 3, pp 193–194 | Cite as

Plasma pharmacokinetics of adriamycin after intrapleural administration

  • Staffan Eksborg
  • Astrid Lindfors
  • Björn J. Cedermark


The plasma pharmacokinetics of adriamycin after intrapleural administration have been studied. The maximum plasma concentration found after intrapleural instillation of 50 mg was 100 ng ml−1, the adriamycin half-life being about 2.5 h.

Large amounts of the drug are adsorbed from the pleura. Hence risks for cardiomyopathy, previously associated with the repeated intravenous administration of adriamycin, must also be considered after intrapleural administration.

Key words

Adriamycin Intrapleural Cancer Chemotherapy Pharmacokinetics Pleural effusions 


  1. 1.
    Blum R H, Carter S K: Adriamycin, a new anticancer drug with significant clinical activity.Ann intern Med 80, 249–259, (1974).PubMedGoogle Scholar
  2. 2.
    Carter S K: Adriamycin—a review.J natn Cancer Inst 55, 1265–1274 (1975).Google Scholar
  3. 3.
    Minow R A, Benjamin R S, Lee E T, Gottlieb J A: Adriamycin cardiomyopathy—risk factors.Cancer 39, 1397–1402 (1977).PubMedCrossRefGoogle Scholar
  4. 4.
    Lenaz L, Page J A: Cardiotoxicity of adriamycin and related anthracyclines.Cancer Treat Rev 3, 111–120 (1976).PubMedCrossRefGoogle Scholar
  5. 5.
    Banks M D, Pontes J E, Izbicki R M, Pierce J M Jr: Topical instillation of doxorubicin hydrochloride in treatment of recurring superficial transitional cell carcinoma of the bladder.J Urol 118, 757–760 (1977).PubMedGoogle Scholar
  6. 6.
    Ozaki Y: Bladder instillation of adriamycin in the treatment of bladder tumours. Report 1: Clinical results.Jap J Urol 68, 934–944 (1977).PubMedGoogle Scholar
  7. 7.
    Eksborg S, Nilsson S O, Edsmyr F: Intravesical instillation of adriamycin—a model for standardization of the chemotherapy.Eur J Urol 6, 218–220 (1980).Google Scholar
  8. 8.
    Eksborg S: Measurements of plasma levels of adriamycin and adriamycinol after intravesical instillation of adriamycin, in:Diagnostics and Treatment ofSuperficial Urinary Bladder Tumours, pp. 55–58. Stockholm Montedison Läkemdel AB, (1979).Google Scholar
  9. 9.
    Jacobi G H, Kurth K H: Studies on the intravesical action of topically administered G3H-doxorubicin hydrochloride in men: plasma uptake and tumour penetration.J Urol 124, 34–37 (1980).PubMedGoogle Scholar
  10. 10.
    Tattersall M H N, Fox R M, Newlands E S, Woods R L: Intracavitary doxorubicin in malignant effusions.Lancet 8112, 390 (1979).CrossRefGoogle Scholar
  11. 11.
    Desai S D, Figueredo A: Intracavitary doxorubicin in malignant effusions.Lancet 8121, 872 (1979).CrossRefGoogle Scholar
  12. 12.
    Kefford R F, Woods R L, Fox R M, Tattersall M H N: Intracavitary adriamycin, nitrogen mustard and tetracycline in the control of malignant effusions.Med J Aust 2, 447–448 (1980).PubMedGoogle Scholar
  13. 13.
    Eksborg S, Ehrsson H, Andersson I: Reversed-phase liquid chromatographic determination of plasma levels of adriamycin and adriamycinol.J Chromatog 164, 479–486 (1979).CrossRefGoogle Scholar
  14. 14.
    Benjamin R S: Pharmacokinetics of adriamycin in (NSC-123127) in patients with sarcomas.Cancer Chemother Rep 58, Part 1, 271–273 (1974).PubMedGoogle Scholar
  15. 15.
    Bachur N R: Adriamycin (NSC-123127) pharmacology.Cancer Treat Rep 6, Part 3, 153–158 (1975).Google Scholar
  16. 16.
    Praga C, Beretta P L, Vigo G Ret al.: Adriamycin cardiotoxicity: a survey of 1237 patients.Cancer Treat Rep 63, 827–834 (1979).PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 1984

Authors and Affiliations

  • Staffan Eksborg
    • 1
  • Astrid Lindfors
    • 1
  • Björn J. Cedermark
    • 2
  1. 1.Karolinska PharmacyStockholmSweden
  2. 2.Department of SurgeryKarolinska HospitalStockholmSweden

Personalised recommendations